Eli Lilly and Co (BSP:LILY34)
R$ 130.52 -2.2 (-1.66%) Market Cap: 3.72 Til Enterprise Value: 3.84 Til PE Ratio: 113.84 PB Ratio: 56.38 GF Score: 73/100

Eli Lilly and Co at Evercore ISI HealthCONx Conference (Virtual) Transcript

Dec 01, 2020 / 07:40PM GMT
Release Date Price: R$25.38 (-3.24%)
Umer Raffat
Evercore ISI Institutional Equities, Research Division - Senior MD & Senior Analyst of Equity Research

Excellent. Thank you all for joining us. Pleasure to have the management team from Lilly join us today. We have Mike from the -- heading the diabetes business. We have Kevin and Sara from the Investor Relations team. And we also have, most importantly, Mike DiFiore from my team as well. So we're all on. Thank you guys for being here.

There's a lot to talk about. And I think, Kevin, correct me if I'm wrong, but the goal today was to only talk oncology, correct?

Michael B. Mason
Eli Lilly and Company - Senior VP & President of Lilly Diabetes

It's going to be a short call.

Kevin Hern
Eli Lilly and Company - VP of IR

If you could fill in a little bit -- Mike would love to do Alzheimer's as well, if you have...

Michael B. Mason
Eli Lilly and Company - Senior VP & President of Lilly Diabetes

Yes, yes. And a little bit of COVID, too, why

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot